All Stories

  1. Age‐Related Changes in the Clinical Picture of Long COVID
  2. Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study
  3. Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts
  4. 2024 Update of the RECOVER-Adult Long COVID Research Index
  5. Sex Differences in Long COVID
  6. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study
  7. Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model
  8. Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort
  9. Opportunities in childhood Sjögren’s disease: results from collaborative roundtable discussions
  10. Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease
  11. New-onset autoimmune disease after COVID-19
  12. Higher Vitamin D Levels before Methotrexate Therapy Initiation Are Associated with Lower Subsequent Mortality in Patients with Rheumatoid Arthritis
  13. Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine
  14. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design
  15. Financial Incentives Are Associated with Lower Likelihood of COVID-19 Vaccination in Northeast Ohio
  16. Red Cell Distribution Width and Absolute Lymphocyte Count Associate With Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis
  17. Optimization of Human Mesenchymal Stem Cells for Rheumatoid Arthritis: Implications for Improved Therapeutic Outcomes
  18. CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease
  19. AB0203 EFFECT OF DOSE ESCALATION OF SUBCUTANEOUS TOCILIZUMAB ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A RANDOMIZED CONTROLLED TRIAL
  20. CD6 is a target for cancer immunotherapy
  21. Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Clinicians From 2010 to 2018
  22. Prioritizing studies of COVID-19 and lessons learned
  23. Attenuation of Murine Collagen‐Induced Arthritis by Targeting CD6
  24. Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE)
  25. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy
  26. SAT0010 FUNCTIONAL BIOMARKER DEVELOPMENT FOR CELL-BASED THERAPY IN RHEUMATOID ARTHRITIS
  27. AB0154 WNT-BETA CATENIN PATHWAY MAY BE UPREGULATED IN ANKYLOSING SPONDYLITIS
  28. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood‐Onset Systemic Lupus Erythematosus
  29. Challenges to Practicing Pediatric Rheumatology
  30. Chemical characterization of Maltese-cross birefringent particles in synovial fluid samples collected from symptomatic joints
  31. What happens when methotrexate is stopped in patients with RA on tocilizumab
  32. Targeting CD6 for the treatment of experimental autoimmune uveitis
  33. CD318 is a ligand for CD6
  34. CD6 as a potential target for treating multiple sclerosis
  35. CD6 Receptor Regulates Intestinal Ischemia/Reperfusion-induced Injury by Modulating Natural IgM-producing B1a Cell Self-renewal
  36. A Point-of-Care Raman Spectroscopy-Based Device for the Diagnosis of Gout and Pseudogout: Comparison With the Clinical Standard Microscopy
  37. Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults
  38. Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis
  39. Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus
  40. Evaluation of musculoskeletal complaints in children
  41. Evaluation of musculoskeletal complaints in children
  42. Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus
  43. Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy
  44. Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
  45. FRI0553 Immunization with Quadrivalent HPV Vaccine (GARDASIL®) Appears Safe and Induces Antibody Response in Jia: an Interim Analysis
  46. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
  47. A109: Insufficient CARRA Registry Data Available to Adequately Evaluate for Associations Between Juvenile Idiopathic Arthritis, Antibody Status, and Smoke Exposure
  48. Laser wavelength dependence of background fluorescence in Raman spectroscopic analysis of synovial fluid from symptomatic joints
  49. Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review
  50. Tocilizumab in Pediatric Rheumatology: The Clinical Experience
  51. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
  52. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein
  53. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
  54. Do Adult Disease Severity Subclassifications Predict Use of Cyclophosphamide in Children with ANCA-associated Vasculitis? An Analysis of ARChiVe Study Treatment Decisions
  55. Increased Sensitivity of the European Medicines Agency Algorithm for Classification of Childhood Granulomatosis with Polyangiitis
  56. Inactive disease and remission in childhood‐onset systemic lupus erythematosus
  57. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
  58. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus
  59. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
  60. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology
  61. Use of atorvastatin in systemic lupus erythematosus in children and adolescents
  62. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus
  63. Mesenchymal Stem Cells: Mechanisms of Inflammation
  64. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
  65. Evaluation of musculoskeletal complaints in children
  66. Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort
  67. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT
  68. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measur
  69. Toward the development of criteria for global flares in juvenile systemic lupus erythematosus
  70. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
  71. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: A secondary analysis of clinical trial data from children with Polyarticular-Cours...
  72. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood
  73. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity
  74. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis
  75. Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort
  76. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
  77. Measures of Disease Activity in Rheumatoid Arthritis: A Clinicians Guide
  78. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial
  79. Sjögren’s syndrome in childhood
  80. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis
  81. Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations
  82. CD166 Expression, Characterization, and Localization in Salivary Epithelium: Implications for Function During Sialoadenitis
  83. Critical Care Myopathy in a Child
  84. Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues
  85. Remittive agents in pediatric rheumatology
  86. CD6: expression during development, apoptosis and selection of human and mouse thymocytes
  87. Evidence for the expression of a second CD6 ligand by synovial fibroblasts
  88. Prevention of infectious complications in rheumatic disease patients
  89. Update on immunosuppressive therapy
  90. Immunosuppressive drug treatment
  91. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on γ-interferon activated keratinocytes
  92. Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes
  93. Mouse CD6: sequence of cDNA and expression of mRNA
  94. Structures on the cell surface. Update from the fifth international workshop on human leukocyte differentiation antigens
  95. Decreased incidence of headache after accidental dural puncture in caesarean delivery patients receiving continuous postoperative intrathecal analgesia
  96. The Boston qualitative scoring system for the Rey-Osterrieth complex figure: Description and interrater reliability
  97. Epidural Patient-Controlled Analgesia After Cesarean Section